APA

LaMontagne K. R., Butler J., Borowski V. B., Fuentes-Pesquera A. R., Blevitt J. M., Huang S., Li R., Connolly P. J. & Greenberger L. M. (20100111). A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. : Angiogenesis.

Chicago

LaMontagne Kenneth R, Butler Jeannene, Borowski Virna B, Fuentes-Pesquera Angel R, Blevitt Jonathan M, Huang Shenlin, Li Ronghua, Connolly Peter J and Greenberger Lee M. 20100111. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. : Angiogenesis.

Harvard

LaMontagne K. R., Butler J., Borowski V. B., Fuentes-Pesquera A. R., Blevitt J. M., Huang S., Li R., Connolly P. J. and Greenberger L. M. (20100111). A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. : Angiogenesis.

MLA

LaMontagne Kenneth R, Butler Jeannene, Borowski Virna B, Fuentes-Pesquera Angel R, Blevitt Jonathan M, Huang Shenlin, Li Ronghua, Connolly Peter J and Greenberger Lee M. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. : Angiogenesis. 20100111.